Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0IRZPG
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
AB-160
|
|||||
| Synonyms |
AB 160; AB-160; AB160; nab-paclitaxel/bevacizumab complex
Click to Show/Hide
|
|||||
| Organization |
Mayo Clinic
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 6 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
Undisclosed
|
|||||
| Antibody Name |
Bevacizumab
|
Antibody Info | ||||
| Antigen Name |
Vascular endothelial growth factor A (VEGFA)
|
Antigen Info | ||||
| Payload Name |
Paclitaxel
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Undisclosed
|
|||||
